Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops

Table 1

Patient characteristics in the tafluprost and DTFC treatment groups.

	Tafluprost (33 eyes of 33 patients)	DTFC (33 eyes of 33 patients)	value
Mean age ± SD (years)	53.6 ± 13.5	54.4 ± 12.2	0.768
Sex (male : female)	17 : 16	16 : 17	0.625
SE (diopter)	−2.9 ± 4.3	−2.4 ± 2.7	0.533
Diagnosis (NTG : POAG)	9 : 24	25 : 8	<0.001
CCT ± SD (μm)	534.6 ± 33.9	545.2 ± 38.3	0.199
Cup-to-disc ratio	0.6 ± 0.2	0.6 ± 0.2	0.853
Pretreatment IOP (mmHg)	18.91 ± 2.53	15.64 ± 1.77	<0.001
Posttreatment IOP (mmHg)	14.18 ± 1.69	13.67 ± 2.73	0.338
IOP reduction (%)	25.0	12.6
Pretreatment OPA (mmHg)	3.08 ± 0.74	2.26 ± 0.77	<0.001
Posttreatment OPA (mmHg)	2.30 ± 0.74	2.03 ± 0.66	0.192
OPA reduction (%)	25.3	10.2
Pretreatment cOPA (mmHg)	3.08 ± 0.74	2.26 ± 0.77	<0.001
Posttreatment cOPA (mmHg)	1.99 ± 0.85	1.90 ± 0.75	0.748
cOPA reduction (%)	35.4	15.9
Baseline VF MD (decibel)	−9.4 ± 7.6	−9.1 ± 5.7	0.909
OCT cpRNFL thickness (micron)	75.7 ± 17.2	76.4 ± 15.4	0.577

NTG: normal tension glaucoma; POAG: primary open angle glaucoma; SE: spherical equivalent; CCT: central corneal thickness; IOP: intraocular pressure; OPA: ocular pulse amplitude; cOPA: corrected OPA; VF MD: visual field mean deviation; OCT: optical coherence tomography; cpRNFL: circumpapillary retinal nerve fiber layer.